Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Mraz S et al. - The majority of adverse events for both products were mild in severity. Thus, while both of these formulations contain the same active ingredient at the same concentration, differences in their efficacy were observed when each treatment was used within its approved labeling guidelines.

Today in Clinical Pharmacology...keeping you current

Anti-platelet Agents
Discovery Medicine, 12/15/09

Use of oral bisphosphonates and risk of venous thromboembolism: A population-based case-control study
Osteoporosis International, 12/15/09

Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up
Acta Neurologica Scandinavica, 12/15/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address